PeptidePedia The community reference

Contract development and manufacturing organisation: difference between revisions

Diff·revision 14 → 15·03:50, 4 May 2025

Difference between revision 14 and revision 15 of Contract development and manufacturing organisation. 3 lines changed; the page grew by 412 bytes.

Revision 14 — 07:38, 12 Apr 2025
StopperingSteff (talk)
rm the vendor-specific packaging detail; not general enough for the article
3,804 bytes ±0
Revision 15 — 03:50, 4 May 2025
FreightFenna (talk)
expand §Consequences for reading documentation
4,216 bytes +412
32Most research-chemical certificates name one of these. That is a limitation of the document rather than evidence about the arrangement behind it, and inferring a specific structure from a document's silence is unsound.32Most research-chemical certificates name one of these. That is a limitation of the document rather than evidence about the arrangement behind it, and inferring a specific structure from a document's silence is unsound.
3333
+34Where a claim about in-house manufacture is made, it is checkable in principle against corporate registration and facility records — the kind of documentary review described at [[VendorInvestigate]] — and not checkable at all by analysis of the material.{{r|reports}}
+35
34== References ==36== References ==
35{{reflist}}37{{reflist}}
36<ref name="ich_q7">International Council for Harmonisation, ''Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients'' (2000).</ref>38<ref name="ich_q7">International Council for Harmonisation, ''Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients'' (2000).</ref>
37<ref name="iso9001">ISO 9001:2015, ''Quality management systems — Requirements''.</ref>39<ref name="iso9001">ISO 9001:2015, ''Quality management systems — Requirements''.</ref>
+40<ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref>
38<ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref>41<ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref>
3942